呋喃唑酮与胶体铋剂联合应用治疗幽门螺杆菌相关性胃炎的疗效观察

BFFECTS 0F COLLOIDAL B1SMUTH SUBCITRATE COMBINED WITH FURAZ0LIDONEOE HELICOBACTER PYLORI ASSOCIATED GASTRITIS

应用胶体铋剂（ＣＢＳ）与不同剂量的呋喃唑酮（Ｆ）联合治疗Ｈｐ阳性慢性胃炎患者。１７３例病人随机分为５组（ＣＢ８组、Ｆ０．２组、ＣＢＳ＋Ｆ０．２组、ＣＢＳ＋Ｆ０．１组、ＣＢＳ＋Ｆ０．０５组）服药４周（ＣＢＳ４周＋Ｆ２周），Ｈｐ根除率分别为２３．３％、５９．３％、１００％、９１．３％和６１．９％；活动性胃炎消退率分别为１４．０％、４８．１％、７０．９％、８６．７％和５３．３％；副作用发生率分别为４．６％、２１．８％、２３．５％、７．１％和１４．８％。ＣＢＳ＋Ｆ０．２及ＣＢＳ＋Ｆ０．１组Ｈｐ根除率及活动性胃炎消退率均显著高于其它三组（Ｐ＜００５）；且ＣＢＳ＋Ｆ０．１与ＣＢＳ＋Ｆ０．２疗效相当，Ｈｐ根除率可达９０％以上，副作用程度明显减轻，是较理想的根除Ｈｐ方案。

n order to find an available medication to eradicate H.pylori (Hp) We tried combinationtherapies of colloidal bismuth subcitrates(CBS) and furazolidone(F)in Hp associated chronicgastritis.The patients were studied with endoscopy and biopsy,and Hp was examined byurease test and Warthin-Starry stain before and after one month of medication. 173 caseswere randomly divided into 5 groups: group l ,CBS (CBS 110mg qid x 28 days);groups 2,F0.2(F0.2 tid x 7 days,then 0.1 qid x 7 days); group 3,CBS + F 0.2 (CBS I I0mg x 28 days + F 0.2tid x 7 days then 1 qid x 7 days); group4,CBS + F0.1(CBS 11Omg x 28 days + F 0.1x14days) ; group 5,CBS + F 0.05(CBS 110mg x 28 days + F 0.05 tid x l4 days).Results : Hperadication rate and side-effects in five groups were as follows: group CBS: 2.3%and 4.6%;F0.2:59.3%and21.8%;CB8+F0.2:10o%and23.5%;CBS+F0.1:91.3%and7.1%;CB8+F0.05: 61.5 的and l4.8%, respectively. Hp eradication rates in group 3 (CBS + F 0.2) and group4 (CBS + F 0. 1) were more satisfactory than the other three groups (P< 0.05).There was nodifference between group 3 and group 4 in the eradication rate of Hp, but the degree ofside-effect in group 4 was significantly less than that in group 3. Conclusion: CBS + F 0.1 isthe effective and therapy for eradication of Hp with less side-effect is also economic.